首页/数据集/Table S6 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer

Table S6 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer

NIAID Data Ecosystem2026-05-01 收录

三阴性乳腺癌治疗

T细胞免疫分析

数据链接：

https://figshare.com/articles/dataset/Table_S6_from_CD25_sup_high_sup_Effector_Regulatory_T_Cells_Hamper_Responses_to_PD-1_Blockade_in_Triple-Negative_Breast_Cancer/30700969 数据链接链接失效反馈

官方服务：

资源简介：

Mass cytometry panels, related to Figure 1

应用场景：

创建时间：

2023-09-15

三阴性乳腺癌治疗

药物靶点发现

Resveratrol (RSV) is known to possess anticancer properties in many types of cancers like breast cancer, in which POLD1 may serve as a potential target. However, the anticancer mechanism of RSV on tri

NIAID Data Ecosystem70

A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy

三阴性乳腺癌治疗

自噬调控

Patients with triple-negative breast cancer (TNBC) often have a poor prognosis largely due to lack of effective targeted therapy. Using a library of seleno-purines coupled to a high-throughput biochem

NIAID Data Ecosystem50

Human TNBC Cells 72h Treatment with 4.5nM OTSSP167 MELK Inhibitor vs. DMSO Control (SUM159). Homo sapiens

三阴性乳腺癌治疗

MEK抑制剂机制

Microarray comparing TNBC cells treated for 72 hours with OTSSP167 MELK Inhibitor and control (DMSO) Overall design: Two-condition arrays: SUM159 cells were treated with either 4.5nM OTSSP167 MELK Inh

NIAID Data Ecosystem40

Cytochalasin D as a potential MAPK family inhibitor for treating triple-negative breast cancer

三阴性乳腺癌治疗

MAPK信号通路

Cytochalasin D, a potent fungal metabolite, has garnered considerable attention due to its diverse biological activities and potential pharmacological applications. Renowned for its ability to disrupt

Taylor & Francis Group2025-02-27 更新50

Small molecule-mediated ERO1A inhibition in restraining aggressive breast cancer

三阴性乳腺癌治疗

ERO1A抑制剂药物研发

Cancer cells adapt to harsh environmental conditions by inducing the Unfolded Protein Response (UPR), of which ERO1A is one of the mediators. ERO1A aids protein folding by acting as a protein disulfid

NIAID Data Ecosystem40

Table S6 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer

资源简介：

相关数据集